Alphabet Inc.

In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 7, 2025), Alphabet Inc. reported 37 stock positions worth $2.4 billion. Its top holding was Ast Spacemobile (ASTS) at 18.2% of the portfolio, followed by Planet Labs PBC (PL, 17.2%) and Arm Holdings PLC-ADR (ARM, 11.5%). Compared with Q2 2025, it opened 2 new positions, sold out of 1, added to 1 and reduced 1. The biggest buy was Prime Medicine (PRME, shares +10%) and the biggest sale an exit from Verve Therapeutics (VERV).

Most Recent 13F
Q2 2026
Location
Mountain View, CA
CIK
0001652044
Portfolio Value
$2.4B (Q3 2025)
SEC Filing
0001652044-25-000096 ↗ filed Nov 7, 2025

Holdings Value

0$20.0B$40.0B$60.0B$80.0B$100.0B Q1 2024: $2.5B Q1 2024 Q2 2024: $2.0B Q2 2024 Q3 2024: $1.8B Q3 2024 Q4 2024: $1.7B Q4 2024 Q1 2025: $1.6B Q1 2025 Q2 2025: $2.1B Q2 2025 Q3 2025: $2.4B $2.4B Q3 2025 Q4 2025: $2.6B Q4 2025 Q1 2026: $4.0B Q1 2026 Q2 2026: $99.1B Q2 2026

Holdings 37 stocks · $2.4B
ASTS Ast Spacemobile Inc. 18.22% 8,943,486 $438.9M No change
PL Planet Labs PBC 17.21% 31,942,641 $414.6M No change
ARM Arm Holdings PLC-ADR 11.52% 1,960,784 $277.4M No change
MTSR Metsera Inc. 8.22% 3,783,528 $198.0M Reduce -23.8%
RVMD Revolution Medicines Inc. 8.01% 4,133,277 $193.0M No change
FRSH Freshworks Inc. Class A 7.92% 16,206,643 $190.8M No change
TEM Tempus AI Inc. Class A 5.20% 1,551,102 $125.2M No change
GTLB Gitlab Inc. Class A 5.10% 2,724,712 $122.8M No change
PATH Uipath Inc. Class A 3.91% 7,034,337 $94.1M No change
PRME Prime Medicine Inc. 3.81% 16,562,498 $91.8M Add +10.0%
DXCM Dexcom Inc. 2.90% 1,036,937 $69.8M No change
MAZE Maze Therapeutics Inc. 2.60% 2,412,471 $62.6M No change
BBOT Bridgebio Oncology Therapeut 1.36% 2,823,126 $32.7M New
FIG Figma Inc. Class A 0.46% 215,582 $11.2M New
GLUE Monte Rosa Therapeutics Inc. 0.45% 1,464,015 $10.8M No change
SANA Sana Biotechnology Inc. 0.41% 2,812,500 $10.0M No change
OSCR Oscar Health Inc. Class A 0.38% 481,988 $9.1M No change
DNTH Dianthus Therapeutics Inc. 0.34% 208,697 $8.2M No change
RLAY Relay Therapeutics Inc. 0.34% 1,568,753 $8.2M No change
BEAM Beam Therapeutics Inc. 0.32% 321,604 $7.8M No change
VERA Vera Therapeutics Inc. 0.29% 241,264 $7.0M No change
LYEL Lyell Immunopharma Inc. 0.20% 293,256 $4.8M No change
FHTX Foghorn Therapeutics Inc. 0.10% 500,901 $2.4M No change
WGS Genedx Holdings Corp. 0.10% 22,711 $2.4M No change
TSHA Taysha Gene Therapies Inc. 0.09% 640,882 $2.1M No change
TCRX Tscan Therapeutics Inc. 0.08% 1,077,080 $2.0M No change
BRNS Barinthus Biotherapeutics PL 0.08% 1,513,644 $1.9M No change
SPRO Spero Therapeutics Inc. 0.07% 889,979 $1.7M No change
TNYA Tenaya Therapeutics Inc. 0.06% 915,705 $1.5M No change
HYPR Hyperfine Inc. 0.05% 898,720 $1.3M No change
EXAS Exact Sciences Corp. 0.05% 23,205 $1.3M No change
AUTL Autolus Therapeutics PLC 0.05% 698,262 $1.1M No change
GUTS Fractyl Health Inc. 0.04% 662,584 $1.1M No change
ALEC Alector Inc. 0.02% 175,866 $521K No change
QUINCE THERAPEUTICS INC 0.01% 189,122 $308K No change
FULC Fulcrum Therapeutics Inc. 0.01% 14,262 $131K No change
RGEN Repligen Corp. 0.00% 383 $51K No change

Portfolio Sells Q2 2025 → Q3 2025
VERV Verve Therapeutics Inc. Sold out 0.00% −6.40
MTSR Metsera Inc. Reduce -23.8% 8.22% +1.61

Portfolio Buys Q2 2025 → Q3 2025
PRME Prime Medicine Inc. Add +10.0% 3.81% +2.07
BBOT Bridgebio Oncology Therapeut New 1.36% +1.36
FIG Figma Inc. Class A New 0.46% +0.46

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 28$99.1BSPCX, PL, ASTS, CME, ARM
Q1 2026 26$4.0BCME, PL, ASTS, RVMD, ARM
Q4 2025 29$2.6BASTS, PL, RVMD, ARM, FRSH
Q3 2025 37$2.4BASTS, PL, ARM, MTSR, RVMD
Q2 2025 36$2.1BASTS, ARM, FRSH, PL, RVMD
Q1 2025 40$1.6BFRSH, ARM, ASTS, RVMD, MTSR
Q4 2024 40$1.7BGTLB, FRSH, ARM, RVMD, CRWD
Q3 2024 42$1.8BGTLB, ARM, RVMD, FRSH, CRWD
Q2 2024 42$2.0BGTLB, ARM, RVMD, CRWD, FRSH
Q1 2024 43$2.5BGTLB, CRWD, DXCM, ARM, FRSH